Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Antiproliferative, antiinvasive, and proapoptotic activity of folate receptor α-targeted liposomal doxorubicin in nonfunctional pituitary adenoma cells.

Liu X, Ma S, Dai C, Cai F, Yao Y, Yang Y, Feng M, Deng K, Li G, Ma W, Xin B, Lian W, Xiang G, Zhang B, Wang R.

Endocrinology. 2013 Apr;154(4):1414-23. doi: 10.1210/en.2012-2128. Epub 2013 Mar 5.

PMID:
23462961
2.

Folate receptor-mediated drug targeting: a possible strategy for nonfunctioning pituitary adenomas?

Lee M, Pellegata NS.

Endocrinology. 2013 Apr;154(4):1387-9. doi: 10.1210/en.2013-1182. No abstract available.

PMID:
23525581
3.

Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas.

Dai C, Cai F, Hwang KC, Zhou Y, Zhang Z, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wei J, Jiao Y, Wei Z, Ma W, Wang R.

Sci China Life Sci. 2013 Feb;56(2):163-73. doi: 10.1007/s11427-012-4433-5. Epub 2013 Jan 18.

PMID:
23334699
4.
5.

Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes.

Xiang G, Wu J, Lu Y, Liu Z, Lee RJ.

Int J Pharm. 2008 May 22;356(1-2):29-36. doi: 10.1016/j.ijpharm.2007.12.030. Epub 2007 Dec 28.

6.

Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.

Sriraman SK, Pan J, Sarisozen C, Luther E, Torchilin V.

Mol Pharm. 2016 Feb 1;13(2):428-37. doi: 10.1021/acs.molpharmaceut.5b00663. Epub 2016 Jan 8.

PMID:
26702994
7.

Differential expression of folate receptor alpha in pituitary adenomas and its relationship to tumor behavior.

Liu X, Ma S, Yao Y, Li G, Feng M, Deng K, Dai C, Cai F, Li Y, Zhang B, Wang R.

Neurosurgery. 2012 May;70(5):1274-80; discussion 1280. doi: 10.1227/NEU.0b013e3182417e76.

PMID:
22089756
9.

Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.

Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A.

Clin Cancer Res. 2000 May;6(5):1949-57.

10.

Vascular targeting of doxorubicin using cationic liposomes.

Wu J, Lee A, Lu Y, Lee RJ.

Int J Pharm. 2007 Jun 7;337(1-2):329-35. Epub 2007 Jan 9.

PMID:
17275230
11.

Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.

Paliwal SR, Paliwal R, Pal HC, Saxena AK, Sharma PR, Gupta PN, Agrawal GP, Vyas SP.

Mol Pharm. 2012 Jan 1;9(1):176-86. doi: 10.1021/mp200439z. Epub 2011 Nov 28.

PMID:
22091702
12.

A Dual-Targeting Octaguanidine-Doxorubicin Conjugate Transporter for Inducing Caspase-Mediated Apoptosis on Folate-Expressing Cancer Cells.

Nair JB, Joseph MM, Mohapatra S, Safeera M, Ghosh S, Sreelekha TT, Maiti KK.

ChemMedChem. 2016 Apr 5;11(7):702-12. doi: 10.1002/cmdc.201600029. Epub 2016 Mar 15.

PMID:
26990462
13.

Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.

Mei L, Liu Y, Zhang Q, Gao H, Zhang Z, He Q.

J Control Release. 2014 Dec 28;196:324-31. doi: 10.1016/j.jconrel.2014.10.017. Epub 2014 Oct 24.

PMID:
25450404
14.

Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.

Zhou X, Zhang M, Yung B, Li H, Zhou C, Lee LJ, Lee RJ.

Int J Nanomedicine. 2012;7:5465-74. doi: 10.2147/IJN.S33965. Epub 2012 Oct 16.

15.

Effect of Hypoxia on DDR1 Expression in Pituitary Adenomas.

Li S, Zhang Z, Xue J, Guo X, Liang S, Liu A.

Med Sci Monit. 2015 Aug 19;21:2433-8. doi: 10.12659/MSM.894205.

16.

Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas.

Fernando MA, Heaney AP.

Mol Endocrinol. 2005 Dec;19(12):3085-96. Epub 2005 Jul 14.

PMID:
16020484
17.
18.

Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.

Yang T, Li B, Qi S, Liu Y, Gai Y, Ye P, Yang G, Zhang W, Zhang P, He X, Li W, Zhang Z, Xiang G, Xu C.

Theranostics. 2014 Aug 24;4(11):1096-111. doi: 10.7150/thno.9423. eCollection 2014.

19.

Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.

Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, Lee RJ.

J Pharm Pharm Sci. 2007;10(3):350-7.

20.

Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor alpha.

He Z, Yu Y, Zhang Y, Yan Y, Zheng Y, He J, Xie Y, He G, Wei Y, Song X.

J Biomed Nanotechnol. 2013 May;9(5):833-44.

PMID:
23802413

Supplemental Content

Support Center